%0 Journal Article
%T Effect of Trimetazidine on Functional Capacity in Patient with Ischaemic Cardiomyopathy (TOFCAPI)
%A Mohsin Ahmed
%A Golam Morshed
%A Mahmood Hasan Khan
%A Md. Arifur Rahman
%A Muhammed Aminur Razzaque
%A Shariful Islam
%A Sayeedur Rahman Khan
%A Chowdhury Md. Kudrat-E-Khuda
%A Salahuddin Anis Shiblee
%A Md. Habibur Rahman
%J International Journal of Clinical Medicine
%P 55-67
%@ 2158-2882
%D 2024
%I Scientific Research Publishing
%R 10.4236/ijcm.2024.152004
%X <strong>Objective: </strong>This study aimed to evaluate the efficacy of trimetazidine on exercise capacity via a six-minute walk test in patients with ischaemic cardiomyopathy and also evaluate the effect of trimetazidine on left ventricular function via echocardiography in the same population. <strong>Methods:</strong> This prospective observational study, conducted at the National Institute of Cardiovascular Diseases in Dhaka, Bangladesh, enrolled 200 patients with ischaemic cardiomyopathy and a depressed left ventricular ejection fraction (LVEF < 35%). We investigated the effects of modified-release trimetazidine on exercise capacity and left ventricular function in ischaemic cardiomyopathy patients with an LVEF less than 35%. The cohort, was divided into Group 1, which received modified-release trimetazidine alongside standard anti-ischaemic therapy and Group 2, which received standard therapy. Patients were subjected to a year-long study with follow-ups at the 1st and 6th months. Using SPSS software, statistical analysis was used to assess treatment-related effects and baseline comparability. <strong>Results:</strong> In this study (n = 200) of ischaemic cardiomyopathy patients, the mean age was 58 years, with 76% of the patients being male. All study subjects received GDMT (Guideline-Directed Medical Therapy) for angina and heart failure. Those who received the modified released form of trimetazidine developed lesions during the 1st and 2nd follow-ups, during which the LVEF, LVIDd, and six-minute walk distance significantly improved (p < 0.05). There was a progressive improvement in functional status, which was statistically highly significant at the second follow-up. <strong>Conclusion:</strong> The findings of the present study demonstrated that the addition of modified-release trimetazidine to GDMT can improve exercise capacity and left ventricular function in patients with ischaemic cardiomyopathy.
%K Bangladesh
%K Heart Failure
%K Exercise Capacity
%K Trimetazidine
%K Ischaemic Cardiomyopathy
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=131326